The use of DPP-4 inhibitors for Covid-19 patients with diabetes might significantly lower the probability of all-cause mortality and severe manifestations of Covid-19.
Endocrinologist Dr Md Feroz Amin said this at a scientific seminar in Dhaka recently.
NIPRO JMI Pharma Limited recently arranged the seminar on “DPP-4 inhibitors and COVID-19 related outcomes among patients with type 2 diabetes” at a hotel in the capital, according to a statement.
Dipeptidyl peptidase-4 (DPP-4) inhibitors are new oral diabetes drugs.
Professor AK Azad Khan, president of Bangladesh Diabetic Association, was present as the chief guest.
Endocrinologists Professor Md Faruque Pathan and Professor Dr SM Ashrafuzzaman were present in the seminar as chairperson and co-chairperson respectively.
Chief guest Professor AK Azad Khan thanked NIPRO JMI Pharma for arranging a scientific seminar in this current situation and praised NIRPO for working with the Diabetic Association of Bangladesh as its scientific partner for a long time in diabetes prevention and treatment.
Chairpersons and co-chairperson also admired NIPRO JMI Pharma for producing several groundbreaking medicines in Bangladesh within a short span of time, which has enriched the diabetes management in Bangladesh.
Md Mizanur Rahman, the CEO of NIPRO JMI Pharma Limited, expressed his gratification to the clinicians for their amazing support in serving the ailing humanity with its world class products.
He also articulated that a good number of latest molecules will be launched soon in the continuation of its regular endeavours.